Your browser is no longer supported. Please, upgrade your browser.
Settings
MCRB Seres Therapeutics, Inc. daily Stock Chart
MCRB [NASD]
Seres Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.43 Insider Own0.70% Shs Outstand41.55M Perf Week-5.47%
Market Cap258.44M Forward P/E- EPS next Y-1.57 Insider Trans-15.34% Shs Float33.87M Perf Month6.69%
Income-98.90M PEG- EPS next Q-0.34 Inst Own77.60% Short Float11.73% Perf Quarter6.32%
Sales28.30M P/S9.13 EPS this Y-9.90% Inst Trans-0.96% Short Ratio11.55 Perf Half Y-17.40%
Book/sh-1.18 P/B- EPS next Y15.60% ROA-75.80% Target Price13.00 Perf Year-29.80%
Cash/sh2.06 P/C3.01 EPS next 5Y- ROE483.60% 52W Range4.42 - 9.75 Perf YTD37.61%
Dividend- P/FCF- EPS past 5Y-67.50% ROI208.90% 52W High-36.21% Beta1.81
Dividend %- Quick Ratio2.20 Sales past 5Y- Gross Margin- 52W Low40.72% ATR0.54
Employees145 Current Ratio2.20 Sales Q/Q241.90% Oper. Margin- RSI (14)49.90 Volatility6.43% 10.14%
OptionableYes Debt/Eq- EPS Q/Q27.10% Profit Margin- Rel Volume0.62 Prev Close6.70
ShortableYes LT Debt/Eq- EarningsMar 14 BMO Payout- Avg Volume343.82K Price6.22
Recom1.90 SMA20-0.99% SMA501.67% SMA200-14.24% Volume214,024 Change-7.16%
Oct-22-18Initiated Chardan Capital Markets Buy $15
Oct-13-17Initiated Oppenheimer Outperform $19
Aug-04-17Reiterated H.C. Wainwright Buy $15 → $19
Feb-01-17Reiterated FBR & Co. Outperform $23 → $18
Aug-12-16Reiterated FBR Capital Outperform $43 → $23
Aug-01-16Reiterated H.C. Wainwright Buy $50 → $15
Aug-01-16Downgrade BofA/Merrill Buy → Neutral
Jul-29-16Resumed H.C. Wainwright Buy $50
Mar-30-16Initiated FBR Capital Outperform $40
Mar-03-16Initiated Guggenheim Buy
Jan-25-16Initiated H.C. Wainwright Buy $55
Oct-22-15Upgrade BofA/Merrill Neutral → Buy
Jul-22-15Initiated Canaccord Genuity Buy $50
Jul-21-15Initiated Leerink Partners Outperform
Jul-21-15Initiated Goldman Neutral
Jul-21-15Initiated BofA/Merrill Neutral
Mar-23-19 08:10AM  Edited Transcript of MCRB earnings conference call or presentation 6-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
Mar-13-19 08:45AM  Seres Therapeutics (MCRB) in Focus: Stock Moves 6.7% Higher Zacks +5.87%
Mar-11-19 02:24PM  Seres Therapeutics Options Volume Peaks After AstraZeneca News Schaeffer's Investment Research +24.85%
01:41PM  Here's Why Seres Therapeutics Stock Soared Today Motley Fool
12:58PM  Seres teams up with AstraZeneca to explore microbiome benefits in cancer treatment American City Business Journals
09:30AM  Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca Business Wire
Mar-06-19 12:13PM  Seres Therapeutics Inc (MCRB) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates Business Wire
Mar-05-19 04:00PM  Seres Therapeutics to Present at Three Upcoming March Conferences Business Wire
Mar-04-19 07:00AM  Seres Therapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Operational Progress Conference Call and Webcast on March 6, 2019 Business Wire
Feb-07-19 09:00AM  Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets Business Wire
Jan-15-19 07:00AM  Seres Therapeutics Announces Chief Executive Officer Transition Business Wire
Jan-04-19 02:29PM  Does Seres Therapeutics, Inc.s (NASDAQ:MCRB) CEO Salary Compare Well With Others? Simply Wall St. +7.60%
Jan-03-19 07:00AM  Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis Business Wire +6.21%
Nov-28-18 08:35AM  Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +5.28%
Nov-19-18 11:31PM  Edited Transcript of MCRB earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-09-18 07:00AM  Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference Business Wire -5.41%
Nov-08-18 09:00AM  Seres Therapeutics (MCRB) Reports Q3 Loss, Misses Revenue Estimates Zacks +9.77%
07:00AM  Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates Business Wire
Nov-05-18 07:00AM  Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018 Business Wire
Oct-22-18 07:00AM  Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer Business Wire
Oct-18-18 08:15AM  New Research Coverage Highlights Altair Engineering, Genomic Health, Seres Therapeutics, REV Group, MACOM Technology Solutions, and New Mountain Finance Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-16-18 08:12AM  Seres Therapeutics Sees Hammer Chart Pattern: Time to Buy? Zacks +9.11%
Oct-03-18 07:00AM  Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018 Business Wire
Aug-24-18 08:10AM  Factors of Influence in 2018, Key Indicators and Opportunity within Seres Therapeutics, Barnes & Noble, Carbo Ceramics, BioLife Solutions, CareDx, and Syntel New Research Emphasizes Economic Growth GlobeNewswire
Aug-14-18 10:07AM  The Microbiome Therapeutics Innovation Group Announces Coalition Formation and Leadership Team PR Newswire
Aug-03-18 09:14PM  Edited Transcript of MCRB earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 11:10AM  Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates Zacks
10:04AM  Seres Therapeutics: 2Q Earnings Snapshot Associated Press
07:00AM  Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates Business Wire
06:30AM  Seres Therapeutics Inc to Host Earnings Call ACCESSWIRE
Jul-25-18 04:27PM  Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018 Business Wire
Jun-19-18 08:30AM  Report: Exploring Fundamental Drivers Behind Diamondback Energy, Global Net Lease, Ambac Financial Group, IDACORP, Francesca's, and Seres Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jun-01-18 07:00AM  Seres Therapeutics to Present at Two Upcoming June Conferences Business Wire
May-29-18 10:48AM  3 Cheapest Stocks With Greatest Potential for Growth InvestorPlace
May-17-18 07:00AM  Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018 Business Wire -5.22%
May-10-18 03:46AM  Edited Transcript of MCRB earnings conference call or presentation 9-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-09-18 07:05AM  Seres Therapeutics: 1Q Earnings Snapshot Associated Press
07:00AM  Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates Business Wire
May-07-18 07:00AM  Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2018 Business Wire
May-04-18 07:00AM  Seres Therapeutics to Present at Two Upcoming May Conferences Business Wire
Apr-25-18 08:15AM  New Research Coverage Highlights BWX Technologies, Sparton, Mercury General, Seres Therapeutics, Caleres, and GCP Applied Technologies Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Apr-17-18 12:00PM  Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting Business Wire +9.91%
Mar-09-18 08:11AM  Edited Transcript of MCRB earnings conference call or presentation 8-Mar-18 1:00pm GMT Thomson Reuters StreetEvents
07:00AM  Seres Therapeutics to Present at Two Upcoming March Conferences Business Wire
Mar-08-18 07:00AM  Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates Business Wire
06:15AM  Seres Therapeutics Inc to Host Earnings Call ACCESSWIRE
Mar-02-18 07:00AM  Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018 Business Wire
Feb-26-18 07:40AM  Report: Developing Opportunities within AeroVironment, Seres Therapeutics, HFF, Fluor, KB Home, and H. B. Fuller Future Expectations, Projections Moving into 2018 GlobeNewswire
Jan-31-18 07:01AM  Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer Business Wire
Jan-04-18 07:00AM  Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference Business Wire
07:00AM  Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis Business Wire
Dec-26-17 11:46AM  ETFs with exposure to Seres Therapeutics, Inc. : December 26, 2017 Capital Cube
Dec-25-17 09:32AM  Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-20-17 07:22AM  Seres Therapeutics, Inc. is trading above its 50 day moving average : MCRB-US : December 20, 2017 Capital Cube
Dec-19-17 07:50AM  Report: Exploring Fundamental Drivers Behind Allstate, Ashford Hospitality Prime, S&P Global, Enzo Biochem, Seres Therapeutics, and HFF New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Dec-04-17 08:28AM  Seres shares drop 7% after news of FDA orphan drug designation for ulcerative colitis therapy MarketWatch -6.16%
07:00AM  Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis Business Wire
Nov-14-17 07:00AM  Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team PR Newswire
06:20AM  Seres teams up with MD Anderson to explore gut's role in drug response American City Business Journals
06:00AM  Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology Business Wire
Nov-13-17 06:31PM  Edited Transcript of MCRB earnings conference call or presentation 8-Nov-17 1:00pm GMT Thomson Reuters StreetEvents -6.58%
Nov-08-17 04:00PM  Seres Therapeutics to Participate in Three Upcoming November Conferences Business Wire
09:50AM  Seres Therapeutics reports 3Q loss Associated Press
07:00AM  Seres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational Progress Business Wire
Nov-07-17 07:00AM  Seres Therapeutics Awarded Grant from CARB-X to Support Development of Microbiome Therapeutic Candidate Business Wire
Nov-02-17 07:00AM  Seres Therapeutics to Host Third Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2017 Business Wire
Nov-01-17 07:00AM  Sigilon Therapeutics Appoints Eric Shaff to Board of Directors PR Newswire
Oct-17-17 09:50AM  ETFs with exposure to Seres Therapeutics, Inc. : October 17, 2017 Capital Cube
Oct-03-17 08:28AM  Seres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : October 3, 2017 Capital Cube
Oct-02-17 08:10PM  How Should You Think About Seres Therapeutics Incs (MCRB) Risks? Simply Wall St. -23.32%
12:03PM  Why Seres Therapeutics Inc. Stock Is Tanking Today Motley Fool
08:00AM  CORRECTING and REPLACING Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis Business Wire
Sep-22-17 11:14AM  ETFs with exposure to Seres Therapeutics, Inc. : September 22, 2017 Capital Cube
Sep-20-17 11:26AM  Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017 Capital Cube +7.12%
Aug-31-17 07:05AM  Seres Therapeutics to Present at the Baird 2017 Global Healthcare Conference Business Wire
Aug-12-17 04:30AM  Edited Transcript of MCRB earnings conference call or presentation 3-Aug-17 12:00pm GMT Thomson Reuters StreetEvents
Aug-04-17 02:05AM  Seres Therapeutics reports 2Q loss Associated Press +6.04%
Aug-03-17 07:05AM  Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress Business Wire
05:30AM  Investor Network: Seres Therapeutics Inc to Host Earnings Call ACCESSWIRE
Aug-02-17 07:05AM  Seres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference Business Wire
Jul-27-17 07:05AM  Seres Therapeutics to Host Second Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2017 Business Wire -5.70%
Jul-21-17 08:20AM  Seres Therapeutics (MCRB) Catches Eye: Stock Gains 9.2% Zacks
Jul-10-17 07:05AM  Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer Business Wire
Jun-13-17 10:16AM  Seres Therapeutics' Stock Up as SER-109 Moves to Phase III Zacks
08:24AM  Seres Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MCRB-US : June 13, 2017 Capital Cube
Jun-12-17 07:07AM  Seres Therapeutics Initiates SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection Business Wire +5.75%
Jun-06-17 04:00PM  Seres Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference Business Wire
Jun-05-17 02:30PM  ETFs with exposure to Seres Therapeutics, Inc. : June 5, 2017 Capital Cube
07:07AM  Seres Therapeutics Announces Completion of Enrollment for SER-287 Phase 1b Study in Patients with Ulcerative Colitis Business Wire
Jun-02-17 10:11AM  Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-11-17 03:50PM  Edited Transcript of MCRB earnings conference call or presentation 4-May-17 12:00pm GMT Thomson Reuters StreetEvents
May-05-17 08:14AM  Seres Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MCRB-US : May 5, 2017 Capital Cube -5.40%
May-04-17 09:12AM  Seres Therapeutics reports 1Q loss Associated Press +8.09%
07:00AM  Seres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress Business Wire
May-01-17 04:00PM  Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences Business Wire
Apr-28-17 04:00PM  Seres Therapeutics to Host First Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2017 Business Wire
Apr-19-17 03:08PM  Seres Therapeutics, Inc. Value Analysis (NASDAQ:MCRB) : April 19, 2017 Capital Cube
Apr-18-17 08:53AM  Seres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : April 18, 2017 Capital Cube
Mar-22-17 01:04PM  SERES THERAPEUTICS, INC. Financials
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. In addition, the company engages in the development of SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-109, a donor-derived purified bacterial spore-based microbiome therapeutic candidate that is in Phase III clinical trial to correct dysbiosis in the colonic microbiome in the setting of recurrent CDI. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DesRosier ThomasChief Legal Officer and EVPJan 28Sale5.755,47131,47816,054Jan 29 06:55 PM
Shaff Eric D.See RemarksJan 28Sale5.754,37825,18812,842Jan 29 06:52 PM
Aunins John G.Chief Technology Officer & EVPDec 17Sale6.3914,28291,31375,250Dec 19 04:11 PM
Aunins John G.See RemarksNov 15Sale8.2614,279117,91289,532Nov 19 04:27 PM
Aunins John G.See RemarksOct 15Sale5.9414,27984,800103,811Oct 16 04:16 PM
Aunins John G.See RemarksSep 17Sale7.2714,279103,875118,090Sep 19 09:22 PM
Pomerantz RogerPresident and CEOSep 07Sale9.001,81016,291213,976Sep 11 04:49 PM
Pomerantz RogerPresident and CEOSep 06Sale9.043,01327,235215,786Sep 06 05:08 PM
Pomerantz RogerPresident and CEOSep 05Sale9.129,50586,714218,799Sep 06 05:08 PM
Aunins John G.See RemarksAug 15Sale7.5714,279108,069132,369Sep 19 09:22 PM
Aunins John G.Chief Technology Officer & EVPJul 15Sale8.1014,279115,726160,927Jul 18 04:58 PM
Pomerantz RogerPresident and CEOJul 11Option Exercise0.711,010717229,314Jul 12 05:15 PM
Pomerantz RogerPresident and CEOJul 11Sale9.011,0109,099228,304Jul 12 05:15 PM
Pomerantz RogerPresident and CEOJul 10Option Exercise0.715,9894,252234,293Jul 10 05:49 PM
Pomerantz RogerPresident and CEOJul 10Sale9.055,98954,208228,304Jul 10 05:49 PM
Pomerantz RogerPresident and CEOJul 09Option Exercise0.7110,9817,797239,285Jul 10 05:49 PM
Pomerantz RogerPresident and CEOJul 09Sale9.1410,981100,351228,304Jul 10 05:49 PM
Pomerantz RogerPresident and CEOJul 06Option Exercise0.7115,36610,910243,670Jul 10 05:49 PM
Pomerantz RogerPresident and CEOJul 06Sale9.1415,366140,507228,304Jul 10 05:49 PM
Pomerantz RogerPresident and CEOJun 29Option Exercise0.714,4963,192232,800Jun 29 05:12 PM
Pomerantz RogerPresident and CEOJun 29Sale9.104,49640,915228,304Jun 29 05:12 PM
Pomerantz RogerPresident and CEOJun 28Option Exercise0.7121,56015,308249,864Jun 29 05:12 PM
Pomerantz RogerPresident and CEOJun 28Sale9.1521,560197,375228,304Jun 29 05:12 PM
Pomerantz RogerPresident and CEOJun 27Option Exercise0.7116,99112,064245,295Jun 27 09:06 PM
Pomerantz RogerPresident and CEOJun 27Sale9.0316,991153,408228,304Jun 27 09:06 PM
Pomerantz RogerPresident and CEOJun 26Option Exercise0.7121,22415,069249,528Jun 27 09:06 PM
Pomerantz RogerPresident and CEOJun 26Sale9.1921,224195,133228,304Jun 27 09:06 PM
Pomerantz RogerPresident and CEOJun 25Option Exercise0.7116,28811,564255,056Jun 27 09:06 PM
Pomerantz RogerPresident and CEOJun 25Sale9.2126,752246,504228,304Jun 27 09:06 PM
Pomerantz RogerPresident and CEOJun 22Sale9.3640,057374,761238,768Jun 22 09:11 PM
Pomerantz RogerPresident and CEOJun 21Sale9.0618,987172,094278,825Jun 22 09:11 PM
Pomerantz RogerPresident and CEOJun 20Sale9.3326,492247,051297,812Jun 22 09:11 PM
Aunins John G.Chief Technology Officer & EVPJun 15Sale8.5714,279122,325170,206Jun 18 04:43 PM
Aunins John G.See RemarksMay 15Sale8.0814,279115,400146,648Sep 19 09:22 PM
Pomerantz RogerPresident and CEOMay 09Sale9.002332,097324,304May 10 04:44 PM
Aunins John G.Chief Technology Officer & EVPApr 25Sale7.5814,279108,266184,485Apr 26 04:55 PM